IL6 and melanoma: Conversely, Linnskog et al37 demonstrated a dose‐dependent increase in Wnt5a expression in IL‐6‐stimulated human melanoma cell lines, HTB63 and A375, whereas Box5, a peptide antagonist of Wnt5a, inhibited IL‐6‐induced cell migration and invasion of the melanoma.